Skip to content

Study · Randomized controlled trial · 2021

10 results

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.

Tuttolomondo A, Cirrincione A, Casuccio A, Del Cuore A, Daidone M, Di Chiara T, Di Raimondo D, Corte VD, Maida C, Simonetta I, Scaglione S, Pinto A

Cardiovascular diabetology4 Jan 2021Cited by 40 (Europe PMC)

PMID33397395 (opens in a new tab)PMCIDPMC7784355 (opens in a new tab)DOI10.1186/s12933-020-01183-5 (opens in a new tab)PepBankPUB-33397395
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

BackgroundRecent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage.AimsWe aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.MethodsMen and women (aged ≥ 50 years) with established or newly detected type 2 diabetes whose HbA1c level was 9.5% or less on stable doses of up to two oral glucose- lowering drugs with or without basal insulin therapy were eligible for randomization. Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly). Arterial stiffness (PWV: pulse wave velocity and augmentation index) and endothelial function (RHI: reactive hyperaemia index) were evaluated at baseline and at three-month and nine-month examination visits. At each visit (at 3 and 9 months), the subjects were also evaluated for glycaemic variables such as fasting plasma glucose (FPG) and HbA1c and lipid variables such as total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels.ResultsAt the three-month follow-up, the subjects treated with dulaglutide showed significantly lower serum levels of FPG and HbA1c than control subjects treated with conventional therapy. At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.ConclusionsOur randomized trial showed that subjects with type 2 diabetes treated with conventional therapy plus 1.5 mg/day of subcutaneous dulaglutide compared with subjects treated with conventional therapy alone showed favourable metabolic effects associated with positive effects on vascular health markers such as arterial stiffness and endothelial function markers. These findings are consistent with previous study findings indicating the strict relationship between cardiovascular risk factors such as systolic blood pressure, total serum cholesterol and LDL levels and cardiovascular events and vascular health surrogate markers.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered FPG versus conventional therapy at three months.

    In plain wordsIn patients with diabetes, dulaglutide lowered fasting blood sugar compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFPG at three months
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    At the three-month follow-up, the subjects treated with dulaglutide showed significantly lower serum levels of FPG and HbA1c than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered HbA1c versus conventional therapy at three months.

    In plain wordsIn patients with diabetes, dulaglutide lowered long-term blood sugar compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at three months
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    At the three-month follow-up, the subjects treated with dulaglutide showed significantly lower serum levels of FPG and HbA1c than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered diastolic blood pressure versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered diastolic blood pressure compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered BMI versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered body mass index compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered total cholesterol versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered total cholesterol compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered LDL cholesterol versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered LDL cholesterol compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseLDL cholesterol
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered FPG versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered fasting blood sugar compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFPG at nine months
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered HbA1c versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide lowered long-term blood sugar compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at nine months
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide lowered pulse wave velocity versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide reduced an arterial stiffness marker compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePulse wave velocity
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In T2D, dulaglutide increased reactive hyperaemia index versus conventional therapy at nine months.

    In plain wordsIn patients with diabetes, dulaglutide improved a blood vessel function marker compared with conventional treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseReactive hyperaemia index
    Study

    n: not reported in source

    Comparator
    Conventional therapy alone
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    1.5 mg once weekly · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At the 9-month follow-up, subjects treated with dulaglutide showed significant lower values of the mean diastolic blood pressure, BMI, total serum cholesterol, LDL cholesterol, FPG, HbA1c and PWV and higher mean RHI values than control subjects treated with conventional therapy.
    2 context sentences
    Summary · context
    We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.
    Summary · context
    Subcutaneous dulaglutide was initiated at the full dose (1.5 mg/day weekly).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.